TipRanks
IDEX Corporation (DE:ID7)
XETRA:ID7
Germany Market
EarningsQ2 2026 Earnings Report

IDEX (ID7) Q2 2026 Earnings Report

0 Followers

DE:ID7 Q2 2026 EPS Results

Actual EPS€1.99
Consensus EPS€1.81
Beat/MissBeat by +€0.18
One Year Ago EPS€1.78

DE:ID7 Q2 2026 Revenue Results

Actual Revenue€791.44M
Expected Revenue€778.35M
Beat/MissBeat by +€13.09M
YoY Revenue Growth+6.38%

Earnings Announcement Details

QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
DE:ID7 Upcoming Earnings
IDEX's next earnings date is estimated for October 27, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DE:ID7 Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 29, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed strong underlying operational performance and demand momentum, with multiple material positives: organic revenue and EPS growth, significant order expansion (28% overall; HST 47%), margin expansion, record orders and improved leverage and cash generation. Management raised full-year guidance and endorsed continued share repurchases while increasing targeted CapEx to support visible future volumes. Key headwinds were limited: segment-level softness in FMT and FSDP (small or single-digit revenue impacts and margin compression from mix/volume deleverage), and a one-time reporting effect from tariff refunds that reduced reported organic growth by ~2% but provided margin/earnings benefit. Overall the positives materially outweigh the challenges.
Company Guidance
IDEX raised its 2026 outlook, now forecasting full‑year organic revenue growth of 5–6% (up from 3–4%), driven by roughly low‑double‑digit growth in HST and slight year‑over‑year gains in FMT and FSDP; adjusted EBITDA margin is now guided to 27.0–27.3% (up from 26.5–27%) and adjusted EPS to $8.70–$8.85 (was $8.35–$8.55), implying high‑single‑digit to low‑double‑digit EPS growth. For Q3 the company expects 5–7% organic growth, adjusted EBITDA margin of 27–27.5% and adjusted EPS of $2.20–$2.25. Management increased 2026 capital expenditures to approximately $110M (from $90M), plans to maintain share repurchases at ~ $75M per quarter (Q2 buybacks were $77M), and noted Q2 cash metrics of $177M free cash flow, >$1.1B liquidity, and gross leverage down to 1.9x (from 2.1x); they also disclosed the Q2 IEEPA tariff refunds provided a $0.08 benefit to adjusted EPS and ~130 bps to adjusted EBITDA margin, and said stronger orders (organic orders +28% in Q2) and backlog supported the raised guidance.
Revenue and Earnings Growth
Consolidated organic sales grew 5% year-over-year in Q2 2026; adjusted EPS increased 12% to $2.32 and adjusted gross margin expanded 110 basis points to 46.4%.
Adjusted EBITDA Margin Expansion
Adjusted EBITDA margin expanded 70 basis points year-over-year to 28.1% (net IEEPA benefit included). Excluding IEEPA refunds, EBITDA margin was toward the high end of Q2 guidance (26.5%–27%).
Exceptional Order Growth and Backlog Visibility
Total organic orders grew 28% in Q2 with record orders exceeding $1 billion; backlog and longer lead-time orders have increased visibility into 2027 for several advantaged end markets.
Health & Science Technologies (HST) Outperformance
HST orders rose 47% organically and HST organic revenue grew 12%; HST adjusted EBITDA margin expanded ~270 basis points year-over-year. HST now derives over one-third of revenue from data center, semiconductor and space & defense markets, and Mott's filtration business boosted recurring revenues within HST's semicon portfolio to ~50%.
Strong Free Cash Flow, Liquidity and Capital Return
Generated $177 million in free cash flow in Q2 and ended the quarter with over $1.1 billion in liquidity. Returned capital via $77 million of share repurchases in Q2 and $54 million of dividends, with planned quarterly repurchases of roughly $75 million for the rest of 2026.
Improved Leverage and Balance Sheet Strength
Gross leverage decreased from 2.1x to 1.9x year-over-year due to strong cash flow and earnings growth, providing flexibility for continued buybacks, bolt-on M&A or portfolio moves.
Raised Full-Year Guidance
Company raised full-year 2026 guidance: organic growth increased to 5%–6% (from 3%–4%), adjusted EBITDA margin guidance raised to 27%–27.3% (from 26.5%–27%), and adjusted EPS guidance increased to $8.70–$8.85 (from $8.35–$8.55), representing high single-digit to low double-digit year-over-year EPS growth.
Investments to Support Growth
CapEx guidance increased from $90 million to approximately $110 million to support select capacity expansions and throughput improvements in high-growth businesses; expenditures are targeted primarily within HST to enable 2027+ volume.
Positive Operational Execution and 8020 Implementation
Company cited strong operational execution, productivity gains and continued implementation of the 8020 program focused on integrating acquired, higher-growth businesses to drive margin expansion and scalability.
IEEPA Tariff Refunds Benefit
Received IEEPA-related tariff refunds in Q2 that produced a net benefit of $0.08 to adjusted EPS and contributed ~130 basis points of benefit to adjusted EBITDA margin for the quarter (segment impacts noted: HST ~90 bps, FMT ~180 bps, FSDP ~120 bps).

DE:ID7 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Oct 27, 2026
2026 (Q3)
1.92 / -
1.745―
2026 (Q2)
1.81 / 1.99
1.7812.08% (+0.21)
2026 (Q1)
1.52 / 1.72
1.50414.29% (+0.21)
2025 (Q4)
1.75 / 1.81
1.7542.94% (+0.05)
2025 (Q3)
1.66 / 1.75
1.6336.84% (+0.11)
2025 (Q2)
1.71 / 1.78
1.7710.49% (<+0.01)
2025 (Q1)
1.41 / 1.50
1.616-6.91% (-0.11)
2024 (Q4)
1.74 / 1.75
1.57311.48% (+0.18)
2024 (Q3)
1.62 / 1.63
1.823-10.38% (-0.19)
2024 (Q2)
1.76 / 1.77
1.874-5.50% (-0.10)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed